Download Frenxit Prescribing Information

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Bad Pharma wikipedia , lookup

Pharmacokinetics wikipedia , lookup

Adherence (medicine) wikipedia , lookup

Pharmacogenomics wikipedia , lookup

Neuropharmacology wikipedia , lookup

Polysubstance dependence wikipedia , lookup

Stimulant wikipedia , lookup

Drug interaction wikipedia , lookup

Hormesis wikipedia , lookup

Dextropropoxyphene wikipedia , lookup

Ofloxacin wikipedia , lookup

Psychopharmacology wikipedia , lookup

Theralizumab wikipedia , lookup

Bilastine wikipedia , lookup

Tablet (pharmacy) wikipedia , lookup

Transcript
T
H
E
R
A
P
E
U
T
I
C
I
N
D
E
X
Frenxit®
Tablet
Description
Frenxit is a preparation of Flupentixol and Melitracen. Flupentixol is a
neuroleptic with anxiolytic and antidepressant properties when given in
small doses, and Melitracen is a bipolar thymoleptic with activating
properties in low doses. In combination the compound renders a
preparation with antidepressant, anxiolytic and activating properties.
Indications
♦ Anxiety ♦ Depression ♦ Apathy ♦ Others are Psychogenic depression,
depressive neuroses, masked depression, psychosomatic affections
accompanied by anxiety and apathy, menopausal depression. Dysphoria
and depression in alcoholics and drug addicts.
Dosage and Administration
Adults : Usually 2 tablets daily (morning and noon). In severe cases the
morning dose may be increased to 2 tablets. Elderly patients : 1 tablet in
the morning.
Maintenance dose : Usually 1 tablet in the morning. In cases of insomnia or
severe restlessness additional treatment with a sedative in the acute phase
is recommended. Second dose should not be taken after 4 pm.
Contraindications
The immediate recovery phase after myocardial infarction. Defects in
bundle-branch conduction. Untreated narrow angle glaucoma. Acute
alcohol, barbiturate and opiate intoxication. Flupentixol and Melitracen
should not be given to patients who have received a MAO inhibitor within
two weeks. Not recommended for excitable patient since its activating
effect may lead to exaggeration of these characteristics.
Precautions
If previously the patient has been treated with tranquilizers with sedative
effects these should be withdrawn gradually.
190
T
H
E
R
A
P
E
U
T
I
C
I
N
D
E
X
Drug Interactions
Flupentixol and Melitracen may enhance the response to alcohol,
barbiturates and other CNS depressants. Simultaneous administration of
MAO inhibitors may cause hypertensive crisis. Neuroleptics and
thymoleptics reduce the antihypertensive effect of Guanethidine and
similar acting compounds and thymoleptics enhance the effects of
adrenaline and noradrenaline.
Side Effects
In the recommended doses side effects are rare. These could be transient
restlessness and insomnia.
Use in Special Population
Pregnancy and lactation : Flupentixol and Melitracen should preferably not
be given during pregnancy and lactation.
Commercial Pack
Frenxit® Tablet : Box containing 100 tablets in 10 x 10’s blister strips.
Each film coated tablet contains Flupentixol Dihydrochloride BP
equivalent to 0.5 mg Flupentixol and Melitracen Hydrochloride INN
equivalent to 10 mg Melitracen.
191